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Dendritic Cells Cross-present Latency Gene Products from
Epstein-Barr Virus–transformed B Cells and Expand
Tumor-reactive CD8⫹ Killer T Cells
By Marion Subklewe, Casper Paludan, Ming L. Tsang,
Karsten Mahnke, Ralph M. Steinman, and Christian Münz
From the Laboratory of Cellular Physiology and Immunology, The Rockefeller University,
New York, New York 10021

Dendritic cells (DCs) are not targets for infection by the transforming Epstein-Barr virus (EBV).
To test if the adjuvant role of DCs could be harnessed against EBV latency genes by cross-presentation, DCs were allowed to process either autologous or human histocompatibility leukocyte antigen (HLA)-mismatched, transformed, B lymphocyte cell lines (LCLs) that had been
subject to apoptotic or necrotic cell death. After phagocytosis of small numbers of either type of
dead LCL, which lacked direct immune-stimulatory capacity, DCs could expand CD8⫹ T cells
capable of killing LCLs that were HLA matched to the DCs. Necrotic EBV-transformed, major
histocompatibility complex (MHC) class I–negative LCLs, when presented by DCs, also could
elicit responses to MHC class II–negative, EBV-transformed targets that were MHC class I
matched to the DCs, confirming efficient cross-presentation of LCL antigens via MHC class I
on the DC. Part of this EBV-specific CD8⫹ T cell response, in both lytic and interferon ␥ secretion assays, was specific for the EBV nuclear antigen (EBNA)3A and latent membrane protein (LMP)2 latency antigens that are known to be expressed at low levels in transformed cells.
The induced CD8⫹ T cells recognized targets at low doses, 1–10 nM, of peptide. Therefore,
the capacity of DCs to cross-present antigens from dead cells extends to the expansion of high
affinity T cells specific for viral latency antigens involved in cell transformation.
Key words: dendritic cells • Epstein-Barr virus • latency antigens • cross-presentation •
cytotoxic T lymphocytes

Introduction
Peptides from infected or malignant cells can be presented
on the MHC products of bone marrow–derived APCs (1).
As the donor cells and APCs need not be genetically
matched at the MHC, antigens effectively “cross” from
one cell to another. Cross-presentation has been known for
some time (2), but only recently have important mechanistic aspects become apparent. Dendritic cells (DCs) prove to
be particularly efficient in cross-presenting antigens on
both MHC class I and II (3–5). For MHC class I, crosspresentation is also termed the exogenous pathway, as the
presented viral or tumor peptides need not be synthesized
endogenously in the APC cytoplasm. Nevertheless, transporters associated with antigen processing (TAP) seem crucial (1, 5). The sources of antigen include virus particles (6),

Address correspondence to C. Münz, Laboratory of Cellular Physiology
and Immunology, The Rockefeller University, DWB407, 1230 York
Ave., New York, NY 10021-6399. Phone: 212-327-7984; Fax: 212327-8875; E-mail: munzc@rockvax.rockefeller.edu

405

bacteria (7), exosomes (8), immune complexes (5), and dying cells (3, 9).
Cross-presentation of dead and dying cells is of special interest in the context of tumor immunology. Tumor cells
typically lack costimulatory molecules, so the processing of
tumor cells can lead to the display of multiple cancer antigens on potent DCs, improving immunogenicity. At this
time, cross-priming during virus infection has been studied
with infectious viruses like influenza and vaccinia (1, 3),
rather than oncogenic viruses in latency or nonlytic states.
In other words, the significance of cross-presentation would
be greatly enhanced if one could demonstrate that latent antigens are processed, and that the corresponding primed T
cells recognize epitopes naturally presented on intact transformed cells. For EBV, latency states are associated with
transformation, so cross-presentation provides a way to
elicit immunity to EBV antigens expressed in tumors like
Hodgkin’s lymphoma and nasopharyngeal carcinoma. Here
we describe the cross-presentation by human DCs of antigens from dying B lymphocyte cell lines (LCLs) trans-
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Abstract

formed with EBV. We will show that human DCs crosspresent apoptotic and necrotic LCLs, giving rise to CD8⫹
effectors that directly recognize HLA-matched, transformed
B cell lines, including such important latency gene products
as (EBV nuclear antigen) EBNA3A and latent membrane
protein (LMP)2. These findings provide a rationale for the
testing of DCs loaded with dead tumor cells to elicit immunity to EBV-associated malignancies in vivo.

Materials and Methods
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Results
DCs Phagocytose Apoptotic or Necrotic LCLs. We first
studied DC phagocytosis of apoptotic and necrotic LCLs.

Figure 1. Immature DCs
phagocytose dying LCLs. (A)
Annexin V/PI staining 6 h after
UV-B treatment for 4 min (apoptosis), four freeze–thaw cycles,
or heating at 56⬚C for 30 min
(necrosis). (B) Immature DCs
stained with PKH 67 (green),
and dying LCLs stained with
PKH 26 (red) before inducing
cell death, were cultured at 1:1.
Phagocytosis was assessed as DCs
double positive for apoptotic (top) or necrotic (bottom) LCLs. FACS®
analyses was performed at different time points, with the optimum phagocytosis at 12 h. To rule out binding vs. uptake of LCLs, cells were cocultured at 4⬚C (left). (C) Fluorescence microscopy showed that ⵑ50% of
the green DCs (dark fluorescence here) had one or more small red LCL
fragments (light fluorescence and arrow) inside the cell (see the XZ plane).
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EBV-transformed LCLs. LCLs were derived from PBMCs of
serologically MHC class I–typed donors, using the supernatant of
the marmoset line B95-8 added in the presence of 1 g/ml cyclosporin A in RPMI 1640/20% FCS/glutamine/gentamicin. In
addition, LCL721.221 (10) and T2 (11) cells were used. All established cell lines were grown in RPMI 1640/10% FCS/
glutamine/gentamicin.
DCs and T Cells. As described (12), PBMCs from leukocyte
concentrates (buffy coats) or whole blood were isolated on Ficoll-Paque (Amersham Pharmacia Biotech) and separated by rosetting into T cell enriched (ER⫹) and depleted (ER⫺) populations. DCs were generated in 3-ml cultures of 2.5 ⫻ 106 ER⫺
cells with 1% human single donor plasma, recombinant human
(rh)GM-CSF and rhIL-4 in a standard way (12) for 6 d, whereupon nonadherent immature DCs were transferred to new plates
at 3 ⫻ 105 cells/ml. Half the medium was replaced by monocyteconditioned medium (MCM) as a maturation stimulus. After
48 h, mature DCs were used fresh or after cryopreservation to
stimulate T cells at a ratio of 1:30 in RPMI 1640/5% human serum/glutamine/gentamicin. CD4⫹ or CD8⫹ fractions were selected from ER⫹ cells with anti-CD4 or anti-CD8 Microbeads,
an MS⫹/RS⫹ column, and a MiniMACS separator (Miltenyi
Biotec). PHA blasts were generated from ER⫹ cells with 1 g/ml
PHA (Sigma-Aldrich) in RPMI 1640/10% FCS/glutamine/gentamicin in 3–5 d.
Induction and Detection of Apoptosis and Necrosis in LCLs. Apoptosis was induced with a 60-mJ UV-B light (UVB) lamp
(Derma Control, Inc.), calibrated to provide 2 mJ/cm2/s, and necrosis either by four freeze–thaw cycles or heating at 56⬚C for 30
min. Cell death was monitored using the Early Apoptosis Detection kit (Kayima Biomedical) to stain with annexin V-FITC
(early apoptosis) and PI (primary or secondary necrosis).
DC Phagocytosis of Apoptotic or Necrotic Cells. 8 h after LCLs
were induced to undergo apoptosis or necrosis, immature DCs
were added at a ratio of 1:1. DCs were matured by adding
MCM. To separate DCs from the LCLs for the experiments represented by Fig. 4, b and c, DCs were stained with PE–antiCD11c (Becton Dickinson) and isolated with anti-PE MicroBeads, MS⫹/RS⫹ column, and MiniMACS separator. More than
95% of the beaded cells were CD11c-PE⫹, CD83-FITC⫹, and
CD20-FITC⫺. To follow phagocytosis, LCLs were dyed red
with PKH26 before inducing cell death and immature DCs green
with PKH67 (Sigma-Aldrich). After coculture for 12 h at a ratio
of 1:1 at 4⬚C and 37⬚C, phagocytosis was monitored as doublepositive cells on the FACS®, or by applying DCs to alcian blue–
coated slides for two-color fluorescence microscopy using an
Olympus epifluorescence microscope. The motorized stage allowed to take 0.5-mm optical sections with a cooled CCD camera (Hamamatsu) and Metamorph software (Universal Imaging
Corp.). Images were deconvoluted by applying a nearest neighbor algorithm provided by Metamorph.

Vaccinia Virus Recombinants and Infection of DCs. Recombinant vaccinia viruses (vv) were expanded on adherent rabbit
RK13 cells and titrated on monkey BSC40 kidney cells. Vv was
added to mature DCs at a multiplicity of infection (MOI) of 2:1
for 1 h at 37⬚C and washed three times with 5% pooled human
serum (PHS). The rate of infection was checked after 6–12 h by
FACS® using intracellular staining for a 29-kD vaccinia early protein with VV1-6B6 antibody (12).
Peptide Loading of DCs. The synthetic peptides FLRGRAYGL (HLA-B8⫹/EBNA 3A) and CLGGLLTMV (HLAA2/LMP 2) were purchased from Genemed Synthesis or Research Genetics, and added to APCs and targets at 1 M in
RPMI 1640 for 1 h at 37⬚C.
T Cell Assays. IFN-␥ enzyme-linked immunospot (ELISPOT)
and 4-h Na251CrO4 cytolysis assays were carried out in a standard
way as described (12).

Cross-presenting DCs Induce CTLs that Lyse LCLs HLAmatched to the DCs. To formally establish presentation
across the MHC, we cocultured immature DCs with dead
HLA-mismatched LCLs (HLA typing in figure legends) for
2 d and tested if the DCs would expand T cells that could
kill LCLs HLA-matched to the DCs. To mature the DCs,
we added MCM along with the dying cells. As expected,
MCM induced a mature phenotype, i.e., CD83, CD25,
and high CD86 and HLA-DR. The DC phenotype was
similar whether or not they had fed on dying apoptotic or
necrotic cells (not shown). The DCs then were used to
stimulate ER⫹ T cells for 14 d, with one restimulation on
day 7 with IL-2. HLA-B8⫹ DCs that had taken up HLAB8⫺ LCLs elicited CTLs that killed HLA-B8–matched, but
not HLA-B8–mismatched, LCLs (Fig. 2 A). Necrotic and
apoptotic LCL fragments were similarly active as sources of
LCL antigens (Fig. 2 A). DCs or dead LCLs by themselves
were incapable of stimulating T cells; in fact, mixtures of
DCs and dead HLA-mismatched LCLs did not induce lysis
of the HLA-mismatched LCLs used for the coculture (Fig.
2 A). This indicates that apoptotic and necrotic cellular
fragments lack either sufficient native HLA molecules and/

Figure 2. DCs induce CTLs that lyse HLA class I–matched but
not mismatched LCLs, after phagocytosis of allogeneic, HLA-mismatched apoptotic or necrotic LCLs. (A) Left. Mature donor A
DCs alone did not stimulate significant cytolysis of HLA class
I–matched donor B (HLA A2⫺B8⫹ LCL: HLA-A1, A3, B7, B8,
Bw6, Cw7, DR4, DRw14, DRw52, DRw53, and DQw3) or
mismatched donor C (HLA A2⫹B8⫺ LCL: HLA-A2, A24, B38,
B46, Bw4, Cw1, DRB1*1502, DRB1*0901, DRB5*0101,
DRB4*01, DQB1*0502, and DQB1*0303) LCLs. Middle and
right. Donor A DCs, loaded with apoptotic or necrotic mismatched donor C LCLs, stimulated donor A CTLs against HLAB8 matched donor B but not mismatched donor C LCLs (middle
and right). One of three similar experiments. (B) Left. Mature
HLA-A2⫹ DCs alone did not stimulate cytolysis against HLA-A2⫹,
HLA class II–negative, EBV⫹ T2 cells (HLA-A2⫹ and low for
HLA-B5 and Cw1) or autologous PHA blasts. After loading with
necrotic HLA class Ia–negative, EBV⫹ LCL721.221 cells (HLADR1, DQ1, DP1) or pulsing with 1 M LMP2426–434 peptide, the
DCs stimulated autologous CTLs recognizing HLA-A2⫹ EBV⫹
T2, but not HLA-A2⫹ EBV⫺ PHA blasts. One of two experiments.
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Apoptosis was induced by UV-B, and necrosis by either
four cycles of freeze–thawing or heating at 56⬚C for 30
min. LCL death was monitored at several times using the
FACS® and staining for annexin V-FITC and PI. Annexin
V single-positive LCLs (apoptosis) predominated 6 h after
UV-B, and annexin V/PI double positives (necrosis) after
repeated freeze–thaw cycles (Fig. 1 A). Freeze–thawing
killed most cells, but live cells remained after UV-B treatment (Fig. 1 A). To follow phagocytosis, the LCLs were labeled with PKH26 before induction of cell death, and 8 h
later, immature PKH67-labeled DCs were added at a ratio
of 1:1. After 12 h of DC/LCL coculture (for maximal uptake), ⵑ50% of the DCs stained double positive (Fig. 1 B).
Some DCs might not have taken up dying LCLs, because
immature DCs generated with GM-CSF and IL-4 contained an already mature, less phagocytic fraction. No double-positive DCs were seen in cocultures on ice (Fig. 1 B).
Phagocytosis of LCL fragments by DCs was verified by fluorescence microscopy (Fig. 1 C), whereas LCLs were incapable of endocytosing LCL fragments under the same conditions (data not shown). Therefore, ⵑ50% of cultured
DCs took up dying apoptotic or necrotic LCLs within 12 h.

or costimulatory molecules to evoke direct alloreactivity.
In addition, alloreactivity mediated through MHC-derived
peptides processed from LCL was not formally required to
induce lytic T cells, as shown by the use of select LCLs in
the experiments of Fig. 2 B. Here, HLA-A2⫹ DCs were
cocultured with necrotic LCL721.221 cells that lacked
MHC class Ia products. The T cells expanded by the
DCs were nevertheless capable of lysing MHC class II⫺ T2
cells that were EBV⫹ and HLA-A2⫹. These cultures also
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Figure 4. The EBV latent antigens EBNA3A and LMP2 are crosspresented by DCs on MHC class I. (A) HLA-A2⫹ DCs were allowed to
phagocytose allogeneic, apoptotic (UVB), or necrotic (freeze–thaw [FT])
LCLs during maturation. The DCs were cultured with syngeneic T cells,
and 7 d later, ELISPOT assays were run with control recombinant vaccinia (vvTK⫺), vvLMP1, or vvLMP2. SFC, spot-forming cell. (B) HLAA2⫹B8⫹ DCs were cultured with apoptotic (UVB) or necrotic (FT)
HLA-A2⫺B8⫺ LCLs for 2 d in the presence of a maturation stimulus.
Then the DCs were stained with anti–CD11c-PE, isolated with magnetic anti-PE beads, and cocultured with ER⫹ T cells at a ratio of 1:30.
7 d later, IFN-␥–secreting T cells were quantified after no restimulation
or restimulation with EBNA3A325⫺333 peptide. (C) HLA-A2⫹ DCs were
charged for 2 d with necrotic (heated) HLA-A2⫺ allogeneic LCLs or
with LMP2426⫺434 peptide, and simultaneously matured with MCM. Mature CD11c-PE⫹ cells were selected with anti-PE beads and used to
stimulate autologous CD8⫹ T cells. After day 14, T cells were tested in
an IFN-␥ ELISPOT assay with LMP2426⫺434 peptide. One of three similar experiments.
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Figure 3. CD8⫹ T cells are effectors for HLA class I–matched LCLs after cross-presentation by DCs. (A) HLA-A2⫹B8⫺ DCs were cultured
with allogeneic HLA-A2-B8⫹ LCLs (HLA-A*0101 homozygous,
B*4002, B*0801, C*0304, C*0701, DRB1*0301, DRB1*1101,
DQB1*0201, and DQB1*0301) at a ratio of 1:1 during maturation. The
DCs were added to CD8⫹ or CD4⫹ positively selected T cells for 14 d.
Lytic activity (4 h 51Cr release assay) is shown on HLA-A2⫹B8⫹ (HLAA2, A1, B39, B8, Cw7, DR1, DR9, DQ1, and DQ3) or HLA-A2⫺B8⫺
(HLA-A*3001, A*3201, B*1302, B*4402, C*0602, C*0501,
DRB1*0401, DRB1*0701, DRB4*01, DQB1*0302, and DQB1*0201)
LCLs, at E/T ratios of 20:1. (B) HLA-A2⫹B8⫹ DCs, after loading with
autologous necrotic or apoptotic LCLs for 2 d in MCM, were added to
CD8⫹ T cells (ratio 1:30). On day 7, wells were split for ELISPOT assays
to detect IFN-␥ upon restimulation with autologous vs. allogeneic HLAA2⫺B8⫺ LCLs. Necrotic LCLs alone did not expand LCL-specific T
cells. One of two similar experiments. SFC, spot-forming cell; apop, apoptotic; necr, necrotic.

showed only background reactivity against PHA blasts autologous to the DCs. As T2 cells are TAP-deficient, the lysis in Fig. 2 B is probably due to recognition of EBV peptides presented in a TAP-independent manner as described
for the LMP2425⫺434 epitope (13) and formally established
below in Fig. 4 C. Accordingly, T cells stimulated with
LMP2425⫺434 on DCs were used as a positive control, and
untreated DCs as a negative control in Fig. 2 B. Therefore,
even when exposed to low doses of dead allogeneic LCLs,
DCs can cross-present EBV antigens that ultimately are
presented by other LCLs HLA-matched to the DCs.
DCs Cross-present Apoptotic or Necrotic, Allogeneic, and Autologous LCLs to CD8⫹ T Cells. To verify that the lysis of
LCLs in Fig. 2 was mediated by CD8⫹ T cells, we again fed
DCs with apoptotic or necrotic LCLs during their maturation, but then added CD8⫹ or CD4⫹ selected T cells for 14 d.

Figure 5. T cells, generated by DCs cross-presenting allogeneic LCLs,
have a high functional affinity. Titration of FLGRAYGL peptide in the
ELISPOT assay after expansion with DCs loaded with synthetic
FLGRAYGL peptide or dying necrotic LCLs. SFC, spot-forming cell.
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independent backgrounds. Both forms of DCs expanded
CD8⫹ T cells of comparable epitope affinity, as indicated
by titrations of FLRGRAYGL peptide (Fig. 5). Half-maximal IFN-␥ responses occurred at 1–10 nM peptide (Fig. 5).
Therefore, DCs extract EBNA3A peptide from latently infected LCLs, and the ensuing cross-presentation generates
CD8⫹ T cells with a high functional affinity.

Discussion
DCs efficiently cross-present dying virus-infected cells
(3). We now find that DCs also cross-present virus-transformed B cells. This extends the exogenous pathway for
MHC class I in several directions: to the processing of B
cells, to viral antigens expressed during latency, and to antigens (EBNA3A, LMP2) that are expressed endogenously
and are likely to be critical for oncogenesis. Importantly,
the cross-presentation we have studied does not require enhanced antigen expression by productive infection, exogenous interferons, or viral vectors and promoters. Also,
transformed LCLs are direct targets for cross-primed CD8⫹
T cells. These findings have potential impact along two
lines, to design new immune therapies for EBV-associated
malignancies, and to understand resistance of most healthy
carriers of EBV to transformation in vivo.
If one considers many EBV-associated malignancies,
such as Hodgkin’s lymphoma and nasopharyngeal carcinoma, only a group of EBV latency genes are known to be
expressed, i.e., EBNA1, LMP1, and LMP2 (14). Two of
these can be presented through the exogenous pathway by
DCs: EBNA1 on MHC class II (4) and in this paper, LMP2
on MHC class I. Furthermore, LCLs serve as targets for
these CD4⫹ (4) and CD8⫹ (this paper; Fig. 3) T cells.
Therefore, the cross-presenting ability of DCs, or the specific loading of DCs with CD4⫹ T cell (EBNA1) and
CD8⫹ T cell (LMP2) antigens, might be explored in DCmediated active immunization against EBV-associated malignancy. By charging DCs with necrotic rather than apoptotic LCLs, there will be much less carryover of viable
tumor (Fig. 1 A). Importantly, by using DCs rather than
tumor cells as the antigen, one can exploit the distinct capacity of DCs (relative to B cells) to produce high levels of
IL-12 (15) and prime efficiently in the T cell areas (16).
Even a stable stock of allogeneic LCLs could be feasible for
charging DCs for immunotherapy, especially in cases in
which autologous LCLs or tumor are difficult to obtain.
Although the DCs will likely process allogeneic peptides
from the LCLs (the so-called indirect pathway of alloMHC presentation) in addition to viral latency antigens,
the former antigens may provide helper function during
immunization. In our hands, allogeneic MHC molecules
on dead LCLs were not directly stimulatory for T cells,
presumably because allo-MHC and/or necessary costimulatory molecules did not maintain their native conformations in sufficient number on dead LCLs (Fig. 2 A). While
this manuscript was under review, stimulation of LCL-specific CD8⫹ T cells was achieved by another group using
DCs loaded with LCL lysates (17). Cross-presentation from

Brief Definitive Report

Downloaded from http://rupress.org/jem/article-pdf/193/3/405/981473/001325.pdf by Rockefeller University user on 10 August 2020

The DCs and target LCLs were not HLA-DR matched
(Fig 3, legend), so one would not expect CD4⫹ CTLs as
occurs with responses to EBNA1 (4). In fact, cross-presentation expanded CD8⫹ T cells that lysed class I–matched
LCLs, whereas CD4⫹ T cells showed only background lysis
against the HLA class II–mismatched targets (Fig. 3 A).
We then verified that DCs expand CD8⫹ T cells after
uptake of autologous, necrotic, or apoptotic LCLs (Fig. 3
B). These T cells secreted IFN-␥ (ELISPOTs) in response
to the autologous LCLs, but not to HLA-A2/B8–mismatched LCLs. Dead autologous LCLs alone did not expand specific CD8⫹ T cells whether the LCLs were killed
via necrosis (Fig. 3 B) or apoptosis (not shown). Therefore,
DCs are able to process allogeneic or autologous LCLs,
directly stimulating CD8⫹ T cells reactive with LCLs
matched at HLA class I loci to the DCs.
DCs Cross-present Defined EBV Latency Gene Products from
Dying LCLs. We next tested for cross-presentation of
known EBV latency gene products. DCs charged with a
low dose of dead LCLs were used to stimulate purified
CD8⫹ T cells for 1 wk. In Fig. 4 A, cross-presentation of
HLA-A2⫺ LCLs allowed HLA-A2⫹ DCs to expand CD8⫹
T cells specific for the LMP2 EBV latency antigen, i.e.,
HLA-A2⫹ DC targets were recognized by the cultures after
infection with vvLMP2 but not vv control (vvTK⫺), or
vvLMP1. To extend these experiments, we purified the
DCs (see Materials and Methods) away from residual dying
LCLs before the DC-T cell coculture. We used antiCD11c magnetic bead selection, as CD11c is abundant on
DCs but not detectable on LCLs. The purified DCs from
HLA-B8⫹ and/or HLA-A2⫹ donors processed the dominant known latency T cell epitopes from allogeneic LCLs,
specifically EBNA3A325⫺333 (restricted by HLA-B8; Fig. 4
B) and LMP2426⫺434 (restricted by HLA-A2; Fig. 4 C).
High Functional Affinity of CD8⫹ T Cells Expanded by
DCs Cross-presenting LCLs. We used the ELISPOT assay
to compare the functional affinity of CD8⫹ T cells expanded by DCs pulsed with viral peptide or cross-presenting necrotic LCLs. After a week of DC-T cell coculture,
we added graded doses of peptide directly to the assay,
avoiding further addition of APCs that increased antigen-
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allogeneic LCLs is most likely due to processing of EBV latency–specific peptides from proteins or larger protein fragments in the dead LCLs, as small peptide epitopes have
very short half-lives in cells lacking their restricting HLA
molecules (18) and are therefore found in only trace
amounts in allogeneic LCLs.
The two latency antigens we have investigated for crosspresentation are of special interest for defense against EBV
in vivo. LMP2 is the only EBV transcript expressed by
EBV⫹ blood memory B cells from healthy donors (19).
LMP2 is thought to provide a growth signal comparable to
that delivered via src-family kinases and the B cell receptor
(20). LMP2 also is a major EBV latency antigen expressed
in Hodgkin’s lymphoma (14), against which CD8⫹ T cell
reactivity can be detected, at least in some HLA-haplotypes
(21, 22). These features make LMP2 potentially important
for the induction of protective CD8⫹ T cell immunity, including for DC-mediated therapy against EBV-associated
malignancy. EBNA3A cross-presentation demonstrates the
efficiency of the exogenous pathway in DCs. The EBNA3
proteins are expressed at lower levels than other EBV latent
antigens (23), and only 1–30 MHC class I–complexed
EBNA3 peptides per cell can be detected on the LCL surface (24). In our studies, we reproducibly observed crosspresentation of LMP2 and EBNA3A when we loaded just
one dying LCL per DC.
We suspect that cross-presentation can begin in vivo during the lytic acute phase of EBV infection (infectious
mononucleosis), when the number of dying infected B cells
must be massive. The immune response to EBNA1, which
is essential for the maintenance of the EBV episome during
host cell division, is providing the first evidence for crosspresentation of EBV antigens to CD4⫹ and CD8⫹ T cells in
vivo. The Gly-Ala repeat region of EBNA1 inactivates the
proteasome in cis, blocking its presentation on MHC class I
by the endogenous pathway (25). However, EBNA1-specific CD8⫹ T cells are known, and these require exogenous
loading of MHC class I molecules for presentation (26, 27).
We have found that DCs also process EBNA1 from transformed LCLs onto MHC class II, expanding EBNA1-specific, CD4⫹ T cells (4). This may occur in vivo, as the
CD4⫹ T cell response in healthy carriers is primarily of the
Th1 type (28). As B cells are not known to be efficient in
producing IL-12 or polarizing T cells to Th1, whereas DCs
are efficient in both regards, IL-12–producing, cross-presenting DCs may induce these EBNA1-specific Th1-type
CD4⫹ T cells in vivo. Therefore, we suggest that the immune response to EBV may depend substantially on the
cross-presentation of EBV-infected cells by DCs.
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